Therakind
Therakind is a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, including paediatric and geriatric populations. They excel in innovating new formulations and drug delivery systems, notably their proprietary DriDose® intranasal device, which aims to improve medicine adherence and ease of use. The company has successfully developed and marketed three products, with a strong pipeline of innovative medicines and drug delivery solutions designed to meet the specific needs of challenging patient groups.
Industries
Nr. of Employees
small (1-50)
Therakind
Third Floor, 314 Regents Park Road, London, N3 2JX, United Kingdom
Patents
Products
Jylamvo
2 mg/mL methotrexate oral solution developed as a palatable liquid formulation for patients with swallowing difficulties and for paediatric dosing.
Buccolam
Pre‑filled oromucosal midazolam syringe for emergency treatment of prolonged acute convulsive seizures in infants, children and adolescents; company provided regulatory strategy and clinical sponsorship for the product.
Ayendi
Nasal diamorphine spray developed for acute severe pain management in children and adolescents; regulatory strategy and clinical development were provided during approval and post‑authorisation studies.
Dry‑powder intranasal unit‑dose device
Single‑use pre‑filled dry‑powder nasal device intended for simple self‑administration or caregiver use; propellant‑free and designed to deliver a measured dose without patient inhalation or coordination.
Dry‑powder intranasal multi‑dose cartridge system
Reusable device body with disposable pre‑filled cartridges or nosepieces enabling multiple doses, configurable dose ranges and reduced single‑use waste compared with fully disposable devices.
Nosatron (preclinical nasal delivery system)
Reusable preclinical delivery device and disposable carriers for animal model testing featuring adjustable air volume/pressure, multiple adaptors, and semi‑automated powder filling.
Jylamvo
2 mg/mL methotrexate oral solution developed as a palatable liquid formulation for patients with swallowing difficulties and for paediatric dosing.
Buccolam
Pre‑filled oromucosal midazolam syringe for emergency treatment of prolonged acute convulsive seizures in infants, children and adolescents; company provided regulatory strategy and clinical sponsorship for the product.
Ayendi
Nasal diamorphine spray developed for acute severe pain management in children and adolescents; regulatory strategy and clinical development were provided during approval and post‑authorisation studies.
Dry‑powder intranasal unit‑dose device
Single‑use pre‑filled dry‑powder nasal device intended for simple self‑administration or caregiver use; propellant‑free and designed to deliver a measured dose without patient inhalation or coordination.
Dry‑powder intranasal multi‑dose cartridge system
Reusable device body with disposable pre‑filled cartridges or nosepieces enabling multiple doses, configurable dose ranges and reduced single‑use waste compared with fully disposable devices.
Nosatron (preclinical nasal delivery system)
Reusable preclinical delivery device and disposable carriers for animal model testing featuring adjustable air volume/pressure, multiple adaptors, and semi‑automated powder filling.
Services
Reformulation, analytical characterisation and compatibility testing of partner drug candidates with dry‑powder intranasal delivery formats to generate de‑risking data prior to development.
Laboratory formulation services for dry‑powder intranasal products, peptide and vaccine candidates, and age‑appropriate oral liquid formulations.
End‑to‑end planning and operational management of multi‑site clinical trials, including studies in emergency and hospital settings and post‑authorisation safety monitoring.
Regulatory planning, dossier preparation and liaison with authorities across EMA, FDA and national agencies, including support for paediatric regulatory pathways.
Business development services including identification and negotiation of distribution, licensing and out‑licensing agreements and support for market roll‑out.
Reformulation, analytical characterisation and compatibility testing of partner drug candidates with dry‑powder intranasal delivery formats to generate de‑risking data prior to development.
Laboratory formulation services for dry‑powder intranasal products, peptide and vaccine candidates, and age‑appropriate oral liquid formulations.
End‑to‑end planning and operational management of multi‑site clinical trials, including studies in emergency and hospital settings and post‑authorisation safety monitoring.
Regulatory planning, dossier preparation and liaison with authorities across EMA, FDA and national agencies, including support for paediatric regulatory pathways.
Business development services including identification and negotiation of distribution, licensing and out‑licensing agreements and support for market roll‑out.
Expertise Areas
- Intranasal drug delivery
- Formulation development for powders and oral liquids
- Clinical trial design and operational management
- Regulatory strategy and submissions (including paediatric pathways)
Key Technologies
- Dry‑powder intranasal delivery
- Pre‑filled unit‑dose delivery devices
- Reusable device bodies with disposable cartridges/nosepieces
- Preclinical delivery adaptors and adjustable nozzles
News & Updates
Therakind announced it received a grant from Innovate UK for the formulation development of a nasal antiemetic candidate using DriDose® technology.
Therakind sponsored the DDL 2024 forum in Edinburgh, showcasing their nasal drug delivery devices and expertise.
Therakind presented a poster on the impact of the filling process on the performance of a spray-dried formulation from the DriDose® nasal powder device.
Therakind announced the completion of a management buy-out, positioning the company for innovation-focused growth.
Therakind announced its sponsorship of the DDL 2023 conference, highlighting their dry powder nasal technology.
Therakind participated in BIO Europe 2024 in Stockholm, seeking partnership opportunities for nasal drug delivery products.
Therakind announced it received a grant from Innovate UK for the formulation development of a nasal antiemetic candidate using DriDose® technology.
Therakind sponsored the DDL 2024 forum in Edinburgh, showcasing their nasal drug delivery devices and expertise.
Therakind presented a poster on the impact of the filling process on the performance of a spray-dried formulation from the DriDose® nasal powder device.
Therakind announced the completion of a management buy-out, positioning the company for innovation-focused growth.
Therakind announced its sponsorship of the DDL 2023 conference, highlighting their dry powder nasal technology.
Therakind participated in BIO Europe 2024 in Stockholm, seeking partnership opportunities for nasal drug delivery products.